No one expects the machinery of progress to roll backwards, but sometimes it seems that no one is watching the speedometer (or manning the brakes, assuming any exist). Is this a fair assessment? If so, should we be worried — and what can we do about it?
In this feature, experts on technology, risk, science, policy and neuroscience discuss risk, innovation and how our values affect our conceptions of both.
Pancreatic cancer is the fourth leading cause of cancer deaths in the United States each year, in part because around four-fifths of cases go undetected until they have reached an advanced stage. But a new, biomarker-based test could soon change all that — and offer a way to monitor treatment outcomes.
Long before they develop neurofibrillary tangles or beta-amyloid plaques, brains with Alzheimer’s disease begin experiencing problems in their cells’ power plants — the mitochondria — that hinder their ability to make energy for cells.
Declines in gene expression related to mitochondria can occur in subjects as young as their early 30s.
Scientists have identified drug targets that could one day make pancreatic cancer less painful — and more survivable — by knocking out key molecular signals. The signals form an essential part of the process by which cancer cells invade and spread through nearby nerves, wounding nerve endings.
Read/listen to my full story at KJZZ’s Arizona Science Desk: